DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Target Lowered at Mizuho

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price lowered by investment analysts at Mizuho from $14.00 to $12.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price target indicates a potential upside of 32.16% from the company’s previous close.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Barclays raised their target price on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Piper Sandler decreased their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Leerink Partners lowered their target price on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a research note on Wednesday, October 14th. Finally, Barrington Research set a $15.00 price target on DENTSPLY SIRONA in a report on Monday, August 10th. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $12.77.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $9.08 on Thursday. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA has a 52-week low of $8.32 and a 52-week high of $14.76. The company has a 50-day simple moving average of $9.95 and a 200-day simple moving average of $10.97. The company has a market capitalization of $1.81 billion, a PE ratio of -3.30, a P/E/G ratio of 1.13 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The company had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. DENTSPLY SIRONA’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities research analysts predict that DENTSPLY SIRONA will post 1.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of DENTSPLY SIRONA in the second quarter worth $283,405,000. Southpoint Capital Advisors LP acquired a new stake in DENTSPLY SIRONA in the first quarter valued at approximately $116,000,000. Edmond DE Rothschild Holding S.A. acquired a new stake in DENTSPLY SIRONA in the second quarter valued at approximately $47,780,000. Paradigm Capital Management Inc. NY purchased a new stake in shares of DENTSPLY SIRONA during the second quarter valued at approximately $39,775,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of DENTSPLY SIRONA by 31.4% during the first quarter. Dimensional Fund Advisors LP now owns 3,559,388 shares of the medical instruments supplier’s stock valued at $41,284,000 after purchasing an additional 850,261 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.